Medpace Holdings, Inc.
MEDP
Rank in Stocks
#1299
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a... Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
Share Price
$622.45
Last synced: 2026-10-19
Market Cap
$17.37B
Change (1 day)
0.64%
Change (1 year)
14.34%
Country
US
Trade Medpace Holdings, Inc. (MEDP)
Category
Healthcare
P/E ratio for Medpace Holdings, Inc. (MEDP)
P/E ratio as of October 2026 TTM: 35.46
According to Medpace Holdings, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.46. At the end of 2024 the company had a P/E ratio of 25.43.
P/E ratio history for Medpace Holdings, Inc. from 2013 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 35.46 | -1.26% |
| 2025 | 35.91 | 41.21% |
| 2024 | 25.43 | -23.62% |
| 2023 | 33.30 | 18.76% |
| 2022 | 28.04 | -34.68% |
| 2021 | 42.92 | 25.80% |
| 2020 | 34.12 | 13.62% |
| 2019 | 30.03 | 16.80% |
| 2018 | 25.71 | -28.98% |
| 2017 | 36.20 | -62.25% |
| 2016 | 95.89 | -175.51% |
| 2015 | -126.99 | 141.75% |
| 2014 | -52.53 | -222.46% |
| 2013 | 42.89 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | 1.96% |
US
|
|
| 39.77 | 12.17% |
US
|
|
| -290.26 | -918.57% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -3.59% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.